What's Happening?
PHARMAP 2026, a key event in the pharmaceutical industry, is focusing on the shift from transactional vendor relationships to strategic partnerships with Contract Development and Manufacturing Organizations (CDMOs) and Contract Manufacturing Organizations (CMOs).
The event features discussions on how pharmaceutical companies are redefining outsourcing to emphasize long-term cooperation, shared risk, and early involvement of CMOs. Notable speakers include Henk Mollee from Astellas Pharma Europe, who will discuss partnership evolution through site divestment, and other industry leaders from Bayer, NTC Pharma, and Abdi Ibrahim Pharmaceuticals.
Why It's Important?
The strategic shift highlighted at PHARMAP 2026 is crucial as it reflects the evolving nature of the pharmaceutical industry, where companies are seeking more collaborative and flexible partnerships. This approach aims to enhance supply chain resilience, quality governance, and innovation. By moving away from purely cost-driven outsourcing, pharmaceutical companies can achieve greater strategic flexibility and value creation. This trend is likely to lead to more robust and efficient drug development processes, ultimately benefiting patients and healthcare systems by ensuring a steady supply of high-quality pharmaceuticals.
